CALL/VERTEX PHARMACEUTICALS/600/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 11:55:12 07/06/2024 pm IST | ||
| 0.023 EUR | +9.52% |
|
| Current month | +475.00% | ||
| 1 month | +187.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 0.023 | +9.52% |
| 06/24/06 | 0.021 | +50.00% |
| 05/24/05 | 0.014 | +133.33% |
| 04/24/04 | 0.006 | +50.00% |
| 03/24/03 | 0.004 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 11:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP93BS |
| ISIN | DE000GP93BS5 |
| Date issued | 17/07/2023 |
| Strike | 600 $ |
| Maturity | 21/06/2024 (13 Days) |
| Parity | 10 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.339 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.3 € |
| Spread % | 93.75% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
